Clinical Trials

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07224672 2026-03-17

ALANIS

60 enrolled

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT05438043 2026-03-16

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT07095452 2026-03-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Multiple Myeloma

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04923893 2026-03-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT06305754 2026-03-13

MK-2870-009

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06353386 2026-03-13

MK-5684-01A

220 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT06824467 2026-03-13

TroFuse-022

770 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05552222 2026-03-12

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT07284758 2026-03-12

MOMENTUM

Phase 2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Multiple Myeloma

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Phase 2 Completed

171 enrolled

Burkitt Lymphoma, Leukemia

NCT05519085 2026-03-11

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT06136624 2026-03-11

OMAHA-003

1,310 enrolled

Phase 1 Active not recruiting

Prostate Cancer Metastatic

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06788912 2026-03-10

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT05583617 2026-03-06

PLYCOM

200 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT06104449 2026-03-06

MK-5684-005

6 enrolled

Prostatic Neoplasms

NCT05623020 2026-03-04

MagnetisMM-6

1,116 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT00343460 2026-03-02

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Phase 3 Completed

1,428 enrolled 21 charts

Nausea, Vomiting

NCT05319730 2026-03-02

MK-3475-06B

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

228 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

46 enrolled 15 charts

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Phase 2/3 Not yet recruiting

Multiple Myeloma, Neoplasms

NCT07428369 2026-02-23

LINKER-MM8

1,570 enrolled

Multiple Myeloma

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Phase 1 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06136598 2026-02-17

MK-5684-001

14 enrolled

Prostatic Neoplasms

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT04162210 2026-02-11

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

302 enrolled 38 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

Multiple Myeloma

NCT06230224 2026-02-06

OLYMPIA-4

216 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1 Recruiting

174 enrolled

Phase 1/2 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT07387926 2026-02-04

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

50 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

127 enrolled

Multiple Myeloma

NCT05020236 2026-02-02

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT06988488 2026-02-02

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

62 enrolled